Baricitinib may be used as 2nd line therapy in patients with persistently active disease and predominant arthritis flares. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor approved for the treatment of rheumatoid arthritis and atopic dermatitis (69). This evidence concerns the gene JAK2 and atopic eczema.